Back to Search Start Over

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

Authors :
Christian Gytz Ammitzbøll
Kristian Stengaard-Pedersen
Merete Lund Hetland
Peter Junker
Mikkel Østergaard
Klaus Kaae Andersen
Torkell Ellingsen
Christian Dehlendorff
Hans Christian Horn
Annette Schlemmer
Mette Yde Dam
Palle Ahlquist
Johnny Lillelund Raun
Anette Jørgensen
Kim Hørslev-Petersen
J.S. Johansen
Sophine B. Krintel
Asta Linauskas
Jan Pødenphant
Hanne Merete Lindegaard
I. Hansen
Source :
Krintel, S B, Dehlendorff, C, Hetland, M L, Hørslev-Petersen, K, Andersen, K K, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H M, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Horn, H C, Jørgensen, A, Raun, J, Ammitzbøll, C G, Østergaard, M, Stengaard-Pedersen, K & Johansen, J S 2016, ' Prediction of treatment response to adalimumab : a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis ', Pharmacogenomics Journal, vol. 16, no. 2, pp. 141-146 . https://doi.org/10.1038/tpj.2015.30, Krintel, S B, Dehlendorff, C, Hetland, M L, Hørslev-Petersen, K, Andersen, K K, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H M, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Horn, H C, Jørgensen, A, Raun, J, Ammitzbøll, C G, Østergaard, M, Stengaard-Pedersen, K & Johansen, J S 2016, ' Prediction of treatment response to adalimumab : a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis ', Pharmacogenomics Journal, vol. 16, no. 2, pp. 141-6 . https://doi.org/10.1038/tpj.2015.30, Krintel, S B, Dehlendorff, C, Hetland, M L, Hørslev-Petersen, K, Andersen, K K, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H M, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Horn, H C, Jørgensen, A, Raun, J, Ammitzbøll, C G, Østergaard, M, Stengaard-Pedersen, K & Johansen, J S 2016, ' Prediction of treatment response to adalimumab : a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis ', The Pharmacogenomics Journal, vol. 16, no. 2, pp. 141–146 . https://doi.org/10.1038/tpj.2015.30
Publication Year :
2014

Abstract

At least 30% of patients with rheumatoid arthritis (RA) do not respond to biologic agents, which emphasizes the need of predictive biomarkers. We aimed to identify microRNAs (miRNAs) predictive of response to adalimumab in 180 treatment-naïve RA patients enrolled in the OPtimized treatment algorithm for patients with early RA (OPERA) Study, an investigator-initiated, prospective, double-blind placebo-controlled study. Patients were randomized to adalimumab 40 mg (n=89) or placebo-adalimumab (n=91) subcutaneously in combination with methotrexate. Expressions of 377 miRNAs were determined using TaqMan Human MicroRNA LDA, A Card v2.0 (Applied Biosystems). Associations between miRNAs and treatment response were tested using interaction analyses. MiRNAs with a P-value

Details

ISSN :
14731150
Volume :
16
Issue :
2
Database :
OpenAIRE
Journal :
The pharmacogenomics journal
Accession number :
edsair.doi.dedup.....60db69177199293d3152077ddf142c70
Full Text :
https://doi.org/10.1038/tpj.2015.30